Literature DB >> 26341042

Level of impact on the public health of universal human immunodeficiency virus screening in an Emergency Department.

Juliana Reyes-Urueña1, Laura Fernàndez-López2, Luis Force3, Manel Daza4, Cristina Agustí5, Jordi Casabona6.   

Abstract

INTRODUCTION: The aim of this study was to determine the prevalence of HIV and the acceptability of rapid testing in an emergency department (ED), Barcelona (6/07/2011 to 8/03/2013).
METHOD: A convenience sample was used, depending on nurse availability in the ED. Participants signed an informed consent. Results were confirmed by conventional methods. RESULT: A total of 2,140 individuals were offered testing, and 5% rejected taking part (107/2,140). Three subjects (3/2,033 [0.15%]) had confirmed reactive test. Individuals with a higher education were more likely to perform a rapid HIV test in ED (P<.005).
CONCLUSION: A low prevalence of new HIV diagnoses was found among participants, although there was a high acceptability rate to perform rapid testing in the ED.
Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Cribado; Diagnostic test; Emergency Department; Hospital; Human immunodeficiency virus; Prueba diagnóstica; Screening; Servicio de Urgencias; Virus de la inmunodeficiencia humana

Mesh:

Year:  2015        PMID: 26341042     DOI: 10.1016/j.eimc.2015.06.014

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  HIV testing strategies employed in health care settings in the European Union/European Economic Area (EU/EEA): evidence from a systematic review.

Authors:  S Desai; L Tavoschi; A K Sullivan; L Combs; D Raben; V Delpech; S F Jakobsen; A J Amato-Gauci; S Croxford
Journal:  HIV Med       Date:  2019-11-14       Impact factor: 3.180

2.  [Post-exposure prophylaxis against HIV, the view from the emergency department - authos´s response].

Authors:  R Escudero-Sánchez; C J Kurt Meier-de-Taboada; E Bartolome-García; P M Rodríguez-de-Bethencourt-Sanjuan; J E Losa-García
Journal:  Rev Esp Quimioter       Date:  2018-03-23       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.